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Abstract  
The airway epithelium secretes proteins that function in innate defense against 
infection. BPI fold-containing family member A1 (BPIFA1) is secreted into airways 
and has a protective role during bacterial infections, but it is not known whether it 
also has an antiviral role. To determine a role in host defense against influenza A 
virus (IAV) infection and to find the underlying defense mechanism we developed 
transgenic mouse models that are deficient in BPIFA1 and used these, in 
combination with in vitro 3D mouse tracheal epithelial cell (mTEC) cultures, to 
investigate its antiviral properties. We show that BPIFA1 has a significant role in 
mucosal defense against IAV infection. BPIFA1 secretion was highly modulated after 
IAV infection. Mice deficient in BPIFA1 lost more weight after infection, supported a 
higher viral load and virus reached the peripheral lung earlier, indicative of a defect 
in the control of infection. Further analysis using mTEC cultures showed that 
BPIFA1-deficient cells bound more virus particles, displayed increased nuclear 
import of IAV ribonucleoprotein complexes and supported higher levels of viral 
replication. Our results identify a critical role for BPIFA1 in the initial phase of 
infection by inhibiting the binding and entry of IAV into airway epithelial cells.  
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Introduction  1 
The airway epithelium has a fundamental role in the initial defense against 2 
pathogens and as such secretes a number of proteins/peptides that function in 3 
innate defense 1. Bactericidal/permeability-increasing (BPI) fold-containing family A1 4 
(BPIFA1; also called SPLUNC1) is a glycoprotein that is highly expressed in the 5 
respiratory epithelium and submucosal glands of the upper airways in mice and 6 
humans 2-9.  The mouse and human BPIFA1 sequences are homologous 8, 10, 11.  7 
Previous studies have demonstrated that BPIFA1 acts as a surfactant 12, can 8 
regulate the amiloride-sensitive epithelial sodium channel, ENaC 13 and affects 9 
mucociliary clearance in the upper airways 14.  It has also been shown to have anti-10 
bacterial roles. For example, Bpifa1 expression is induced after Mycoplasma 11 
infection, enhancing IL-8 production and bacterial clearance 15. BPIFA1 also has a 12 
role in defense against Klebsiella pneumoniae 16, possibly acting through modulation 13 
of macrophage function 17.  Less is known about any anti-viral role of BPIFA1, 14 
although our previous work has shown modulation of BPIFA1 levels after murine γ-15 
herpesvirus 68 infection 18.  16 
Influenza A virus (IAV) is an enveloped RNA virus of the Orthomyxovirus 17 
genus. Seasonal influenza is a major cause of respiratory infection resulting in 18 
substantial morbidity, mortality and thus economic burden worldwide 19. Pandemic 19 
influenza strains emerge sporadically as a result of genetic reassortment and are a 20 
substantial global health concern 20. There are vaccines and antiviral drugs to 21 
combat influenza. However, due to rapid virus evolution, vaccines need to be re-22 
formulated and re-administered most years 21 and resistance against antiviral drugs 23 
is emerging 22. It is therefore important to understand how intrinsic and innate 24 
4 
 
mechanisms modulate influenza virus infection and how these may be used to 25 
develop novel therapeutic interventions. 26 
The negative-sense, single-stranded genome of IAV comprises eight 27 
segments of viral RNA which are separately encapsidated into ribonucleoprotein 28 
particles (RNPs) 23. Infection and entry of IAV into cells involves viral attachment, via 29 
the hemagglutinin (HA) glycoprotein that is embedded in the virion membrane, to cell 30 
surface receptors that contain sialic acid 24.  After binding, virus particles enter the 31 
cell by receptor-mediated endocytosis.  Fusion of the virus membrane with the 32 
endosomal membrane results in release of RNPs into the cytoplasm 24, 25 which are 33 
then imported into the nucleus , where genome replication and transcription of viral 34 
genes take place 26. Understanding the entry process and how the host counters it is 35 
critical to uncovering inhibitors with therapeutic potential. 36 
In this study, we used transgenic mouse models combined with in vitro 3D-37 
culture systems to show that BPIFA1 has a role in the intrinsic defense against IAV 38 
infection. 39 
 40 
Results 41 
BPIFA1 expression after IAV infection.  42 
To determine changes in BPIFA1 levels following IAV infection, C57BL/6J mice were 43 
infected intranasally (i.n.) with 103 pfu IAV X-31 (or as controls with u.v.-inactivated 44 
virus or mock-infected) and analyzed at time-points post-infection (p.i.).  IAV X-31 is 45 
a mouse-adapted H3N2 strain that generates a sub-lethal infection 27.  It thus models 46 
most of the IAV-associated disease in humans and also allows for analysis over an 47 
extended time-course.   48 
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Firstly, levels of BPIFA1 in broncho-alveolar lavage (BAL) were accurately 49 
quantified using (Wes™; ProteinSimple). The results (Fig. 1) showed BPIFA1 levels 50 
decreased dramatically after infection (100-fold) to a nadir at day 7 p.i. before 51 
returning to a level that was not significantly different to uninfected mice by day 14 52 
p.i. u.v.-inactivated virus did not affect the levels of BPIFA1 as measured at day 5 p.i. 53 
Next, the pattern and quantity of BPIFA1 staining was determined by 54 
immunohistology (IH).  In mock-infected mice, BPIFA1 was abundant in the 55 
epithelium of the trachea and bronchi (Fig. 2A, B arrows) but present only within 56 
scattered cells in the bronchioles (Fig. 2C, arrows) and absent in the surrounding 57 
alveoli (Fig. 2C). Following infection with IAV, a substantial decrease in the number 58 
of BPIFA1-positive cells was observed and confirmed by the quantitative analysis 59 
that showed a 4 – 8-fold (p <0.05) decrease in the percentage area stained in the 60 
trachea and bronchi respectively to day 7 p.i.; at this point, there were foci of erosion 61 
with reduced cell height, loss of cilia, loss of cellular polarity and occasional loss of 62 
epithelial cells.  Recovery of levels of BPIFA1 and evidence of epithelial regeneration 63 
with foci of multilayered epithelium and mitoses was seen by day 14 p.i. (Fig. 2A, B).  64 
The intensity of BPIFA1 staining in the positive areas (i.e. in individual epithelial 65 
cells) did not decrease significantly in the trachea, but in the bronchi a similar pattern 66 
to that of area stained was noted with an initial decrease followed by a gradual 67 
recovery.  In contrast, in bronchioles the intensity of staining in epithelial cells 68 
increased five-fold to day 14 p.i., whilst the number of positive cells (area stained) 69 
increased three-fold by day 14 p.i. (Fig. 2C).  70 
 71 
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Mice deficient in BPIFA1 support higher levels of IAV replication.  72 
To determine the role of BPIFA1 in defense against IAV, BPIFA1-deficient mice 73 
(Bpifa1-/-) were generated as described in supplementary data and S1 Fig. (A). 74 
Bpifa1-/- mice expressed no detectable BPIFA1 protein in the lungs (S1 Fig. (B)), but 75 
did not exhibit any morphological changes or altered distribution of cell types in 76 
airways and alveoli (S1 Fig. (C); described in supplementary data). 77 
C57BL/6J and Bpifa1-/- mice were infected i.n. with 103 pfu IAV X-31. The 78 
weight of the mice and lung virus titers were determined over a 28-day period.  The 79 
results (Fig. 3A, B) showed that wt mice were readily infected with IAV. They lost 80 
weight (max. 5%; day 6 p.i.) before recovering. Titers of IAV increased in the lungs, 81 
peaking at 106 pfu/g tissue on day 5 p.i. Infection in Bpifa1-/- mice followed a similar 82 
course. Weight loss was significantly greater (p < 0.01) in Bpifa1-/- mice (12% at day 83 
6 p.i.). In addition, IAV titers were significantly (p < 0.05) and at least 1 log10 higher at 84 
all time-points. Virus was not detectable in either group at days 7 and 14 p.i. 85 
To control for potential developmental adaptation in the knockout mice, a club 86 
cell-specific, tamoxifen (tmx)-inducible conditional knockout mouse strain (Bpifa1loxP; 87 
Scgb1a1-CreERTM) was generated as described in the S1 text. Western blot analysis 88 
of lung tissue confirmed a 9-fold knockdown in the level of BPIFA1 in Bpifa1loxP; 89 
Scgb1a1-CreERTM mice after tmx treatment as compared with mice that were treated 90 
with carrier (Fig. 3C).  91 
Bpifa1loxP; Scgb1a1-CreERTM mice were treated with either carrier (vegetable 92 
oil) or tmx and, along with untreated Bpifa1loxP; Scgb1a1-CreERTM and Bpifa1-/- mice, 93 
were infected i.n. with IAV. Virus titers in the lungs were determined at day 7 p.i.  94 
The results (Fig. 3D) showed that titers of infectious virus were significantly lower in 95 
untreated or carrier-treated mice than in tmx-treated Bpifa1loxP; Scgb1a1-CreERTM 96 
7 
 
mice or Bpifa1-/- mice. Thus, reduction of BPIFA1 expression using either total or 97 
conditional knockout of BPIFA1 enabled IAV to be more pathogenic and replicate to 98 
higher titers in the lungs of infected mice.  99 
 100 
BPIFA1 limits the initial spread of IAV in vivo.  101 
To assess whether BPIFA1 influenced the distribution of IAV infection, C57BL/6J 102 
and Bpifa1-/- mice were infected and IAV-infected cells identified by IH.  At day 1 p.i., 103 
IAV antigen was seen within, and adjacent to foci of necrotic respiratory epithelial 104 
cells in the nasal cavity, trachea, bronchi and proximal bronchioles of both wt and 105 
Bpifa1-/- mice (S2 Fig., arrows).  However, in Bpifa1-/- mice, epithelial cells in the 106 
distal bronchioles were found to be infected and macrophages in alveoli around the 107 
infected bronchioles were positive for IAV (Fig. 4. arrows and red arrowheads 108 
respectively).  In contrast, IAV antigen was not observed in distal bronchioles and 109 
alveoli of wt mice. At subsequent days post-infection there were no differences in the 110 
distribution of IAV antigen between wt and Bpifa1-/- mice.   111 
Thus, in the absence of BPIFA1, IAV infection reached the distal airways and 112 
alveoli earlier during infection.  113 
 114 
BPIFA1 restricts IAV infection in normal epithelial cells.  115 
Given the differences in viral titer as early as day 1 p.i., we hypothesized that one 116 
function of BPIFA1 could be to influence directly the infection of epithelial cells. To 117 
investigate this, tracheal cell cultures were established from mice and cultured at the 118 
air-liquid interface to generate well-differentiated cultures (mTEC) 28, 29. The 119 
validation of these cultures from wt mice is presented in supplementary data and S3 120 
Fig. Differentiated mTEC ALI cultures displayed phenotypic features associated with 121 
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complex populations of cells including ciliated cells (β-tubulin, FoxJ1), BPIFA1, 122 
mucin (MUC5B), and SCGB1A1 (CCSP)-expressing cells that matched with the 123 
features of the native rodent airway epithelium.  The cultures from Bpifa1-/- mice had 124 
similar levels of ciliogenesis (β-tubulin staining) and mucin (MUC5B staining) to 125 
those from wt counterparts (S4 Fig.). Quantification of β-tubulin-staining showed that 126 
approx. 17% of cells were ciliated in both types of cultures. In wt cultures, 24% of 127 
cells were BPIFA1 positive and were non-ciliated. Thus, mTEC ALI cultures are 128 
highly representative of mouse airway epithelium and an ideal model to study the 129 
role of BPIFA1 during infection.    130 
mTEC ALI cultures from wt and Bpifa1-/- mice were infected with IAV (0.1 131 
pfu/cell) and infection analyzed by immunofluorescence (IF). In wt mTEC ALI cells, 132 
IAV antigen was observed predominantly in epithelial cells that did not express 133 
BPIFA1, at both 24 and 48 h p.i. (Fig. 5B, C). An increased number of cells 134 
containing IAV NP antigen was seen in Bpifa1-/- mTEC ALI cultures as compared 135 
with wt cells at both time-points (Fig. 5E, F). Quantification revealed a >2-fold and 136 
nearly 2-fold higher intracellular IAV NP load in Bpifa1-/- than in wt mTEC cultures at 137 
24 h p.i. and 48 h p.i. respectively (Fig. 5G; p < 0.05). There was also a significant 138 
increase in infectious IAV titer in apical wash fluid from Bpifa1-/- compared with wt 139 
cells (Fig. 5H). Thus, BPIFA1 inhibits the infection of normal (mTEC ALI) cells by IAV 140 
at a stage up to or before early viral gene expression. 141 
 142 
BPIFA1 limits the import of IAV into epithelial cells.  143 
Import of virus ribonucleoprotein (vRNP) complexes into the nucleus is one of the 144 
initial steps of the IAV replication cycle.  To investigate whether BPIFA1 influences 145 
the early stages of IAV infection, day 14 mTEC ALI cultures were infected with IAV. 146 
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Import of RNP complexes into the nucleus was then assessed by 147 
immunofluorescence analysis using anti-IAV NP. Blocking protein synthesis with 148 
cycloheximide (CHX) was performed to distinguish imported RNPs from de novo NP 149 
production. The amount of purified virus used was sufficient enable detection of RNP 150 
import in 100% of cells in an equivalent assay performed on MDCK cells (data not 151 
shown). The results (Fig. 6A, B) showed that in the absence of CHX, IAV NP was 152 
readily observed 4 h after infection in the nuclei of cells from wt mice but, as with the 153 
previous experiment, was present in 3.5x more nuclei in cells from Bpifa1-/- mice. In 154 
the presence of CHX, RNP complexes were observed in the nuclei of 1% of wt cells 155 
but in a significantly (p < 0.05) higher proportion (25x) of nuclei in Bpifa1-/- cells (Fig. 156 
6A right panels, B, C).  Thus BPIFA1 appreciably decreased the number of cells with 157 
visible accumulation of IAV RNPs after infection, indicating that it acts at an early 158 
stage of the viral life cycle.      159 
 160 
BPIFA1 inhibits IAV binding to respiratory epithelial cells.  161 
To determine if BPIFA1 affected virus binding, mTEC ALI cultures derived from 162 
Bpifa1-/- and wt mice were incubated with Alexa Fluor 488-labelled IAV (IAV-488) 163 
and bound virus was assessed by confocal microscopy. The amount of labelled virus 164 
used was sufficient to enable detection of binding in 100% of cells in an equivalent 165 
assay performed on MDCK cells (data not shown). wt cells showed IAV binding 166 
predominantly to the surface of Foxj1-positive (ciliated) cells that were negative for 167 
BPIFA1 (Fig. 7A). The BPIFA1-positive sub-population of cells (non-ciliated; S3 Fig. 168 
A, C) presented as focal clusters in mTEC ALI cultures (outlined in yellow) and were 169 
predominantly free from IAV-binding (Fig. 7A). Analysis of the distribution of α2,3-170 
linked and α2,6-linked sialic acid residues using the lectins MAA and SNA 171 
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respectively showed that there were numerous cells with α2,3-linked residues on the 172 
cell surface in both wt and Bpifa1-/- cultures (mean n = 3; 25% and 22% respectively) 173 
and that these were on the BPIFA1-negative cells (S5 Fig. (A)). The few α2,6-174 
positive cells present in the wt and Bpifa1-/- cultures (mean n = 3; 3% and 5% 175 
respectively) were mostly BPIFA1-positive (S5 Fig. (B - E)). Quantification of bound 176 
IAV-488 showed that the integrated fluorescence intensity from Bpifa1-/-  cells was 4 177 
fold greater than that from wt cells (Fig. 7B, C). Thus, our data show that IAV bound 178 
predominantly to ciliated cells that were BPIFA1-negative, α2,3-linked sialic acid-179 
positive, and that the presence of BPIFA1 decreased the binding of IAV to these 180 
cells.  181 
182 
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 183 
Discussion 184 
BPIFA1 is constitutively expressed and secreted by the airway epithelium 2, 6, 185 
7, 18, 30, 31 including the submucosal glands 9, 28, 30, 31. However, its precise biological 186 
functions remain elusive. Our studies have uncovered an important role for BPIFA1 187 
in the host defense against IAV infection. BPIFA1 levels were modulated after 188 
infection and genetic knockout of BPIFA1 led to a higher viral titer both in vivo and in 189 
mTEC ALI cultures. There was also greater nuclear import of virus RNP complexes 190 
and binding of virus to cells in mTEC cultures lacking BPIFA1. 191 
BPIFA1 has previously been shown to have a defensive role in M. 192 
pneumoniae and K. pneumoniae infection, enhancing bacterial clearance and 193 
inhibiting biofilm formation 15, 16. Here we show for the first time, that BPIFA1 also 194 
has a major role in the defense against IAV. Notably higher weight loss was 195 
observed and higher viral titers (> 1 log10) were recovered from the lungs of Bpifa1-/- 196 
mice as compared to wt controls. A more rapid spread of IAV to the lung 197 
parenchyma was also seen in Bpifa1-/- mice. Specifically, IAV antigen was observed 198 
in the bronchiolar epithelium and alveoli of Bpifa1-/- but not of wt mice at 24 h p.i. 199 
indicating a possible role for BPIFA1 both in intrinsic or innate defense during early 200 
infection and in the adaptive immune response to IAV. The higher viral titers in lungs 201 
after conditional knockdown of BPIFA1 in Scgb1a1-expressing club cells indicates 202 
that the observations seen in the Bpifa1-/- mice are not due to developmental 203 
adaptations to the total loss of BPIFA1 expression.   204 
 To investigate intrinsic functions of BPIFA1 in the airway epithelium we 205 
cultured mTEC cells from wt and Bpifa1-/- mice. Although we did not formally rescue 206 
the Bpifa1-/- cells using exogenous protein, we controlled for differences between 207 
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cultures by performing extensive phenotypic characterization. Thus, approximately 208 
25% of the cells in wt mTEC had α2,3-linked sialic acid (SA) residues on the surface. 209 
These cells were BPIFA1-negative. A similar proportion of cells (22%) were α2,3 SA-210 
positive in the Bpifa1-/- cultures. Very few cells on wt and Bpifa1-/-  cultures were α2,6 211 
SA-positive (3% and 5% respectively). Mouse-adapted IAV strains such as those 212 
used in this study (X-31 and PR8) will use both α2,3- and α2,6-linked and sialic acid 213 
residues as a receptor 32, 33. The similar proportions of cells with α2,3- and α2,6-214 
linked and sialic acid residues between wt and Bpifa1-/- cultures indicates that 215 
differences in infection and binding between wt and Bpifa1-/- are due to the absence 216 
or presence of BPIFA1 and not differences in the number of cells expressing 217 
receptors.  Infection of mTEC cultures with IAV paralleled our observations in vivo in 218 
that there was a significantly more rapid spread and higher viral titers in cultures 219 
lacking BPIFA1. In line with the distribution of α2,3-linked sialic acid receptors, IAV 220 
had a preference for infecting the BPIFA1-negative population. This confirms a role 221 
for BPIFA1 in the intrinsic defense against IAV at the airway epithelium during the 222 
first few days of infection and shows that the secreted protein exerts its effects on 223 
the epithelial cell surface rather than solely in the cells that produce it. 224 
Further analysis revealed a much greater import of IAV RNPs into the nuclei 225 
of cells and significantly increased virus binding in the Bpifa1-/- cultures. The fact that 226 
only a percentage of cells were infected in these assays reflects in part the complex 227 
nature of mTEC ALI cultures and where only a proportion of the cells express the 228 
α2,3- and α2,6-SA receptors. The greater level of inhibition in the RNP import assay 229 
compared to the binding assay suggests an important role for BPIFA1 in decreasing 230 
post-binding entry into cells via endosomes as well as initial binding of IAV to normal 231 
ciliated epithelial cells in airways. BPIFA1 is secreted and is present in the periciliary 232 
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layer 34 so it is easy to envisage how it might be part of a barrier to IAV infection at 233 
the epithelial surface. We did not characterize whether and how BPIFA1 binds to 234 
virus particles. However, BPIFA1 could either form a non-specific barrier to IAV 235 
engaging with cellular receptors, or bind to IAV and prevent receptor interactions. 236 
Gel-forming mucins such as MUC5AC inhibit virus infection 35 and BPIFA1 has been 237 
shown to associate with the mucus rich portion of the pericellular lining fluid 34, 36.  It 238 
has been hypothesized that in the case of IAV this is due to competitive inhibition for 239 
receptors as MUC5AC from mice contains abundant α2,3-linked sialic acid residues 240 
35.  The glycosylation on BPIFA1 contains sialic acid residues 37 and could potentially 241 
act by binding to IAV particles via specific sialic acid-HA interactions.  Alternatively, 242 
BPIFA1 is a member of the wider tubular lipid-binding (TULIP) superfamily 38, has a 243 
hydrophobic cavity and binds several lipids found in mammalian membranes 39. It 244 
therefore has the potential to bind to lipids found in the IAV membrane and interfere 245 
with receptor binding and endosomal fusion. Further studies are required to 246 
determine precisely how BPIFA1 blocks binding and entry of IAV into normal 247 
epithelial cells.  248 
Previous studies have shown that infection by a number of pathogens (e.g. P. 249 
aeruginosa, S. pneumoniae, M. pneumoniae, murine γ-herpesvirus 68 and IAV) 250 
cause an initial transient increase in secretion of the protein in the first 2 - 3 hours 251 
post infection but this is followed by a decrease over 2 - 7 days 15, 18, 40. Our results in 252 
vivo extend these observations using IAV (Figs. 1 - 2). Decrease in BPIFA1 levels 253 
after infection is mediated by pathogen-associated molecular patterns (PAMPs) and 254 
IFN-γ 40.  The IAV strains used here target BPIFA1-negative ciliated epithelial cells 255 
and BPIFA1 is produced by non-ciliated epithelial cells. Thus, although IAV induces 256 
necrosis of respiratory epithelial cells, the decrease in BPIFA1 expression is unlikely 257 
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result from direct killing of BPIFA1-expressing cells. Also, intact respiratory epithelia 258 
exhibited decreased BPIFA1 expression at day 7 p.i. (Fig. 2). IAV induces signaling 259 
by a number of PAMPs and so the decrease in BPIFA1 could be due to this 260 
mechanism 41.  Inactivated IAV had no effect suggesting that active replication is 261 
required to mediate a decrease in BPIFA1 levels.  After resolution of the initial 262 
infection, BPIFA1 levels returned to pre-infection levels in BAL and the tracheal and 263 
bronchial epithelium.  264 
It seems unlikely that BPIFA1 has evolved to have a role in the defense 265 
against IAV alone and thus it is likely that the protein will influence the pathogenesis 266 
of other viruses. It has been shown to have an inhibitory effect on the replication of 267 
Epstein-Barr virus (a membrane-bound herpesvirus) in lymphoblastoid cells 42. 268 
Down-regulation of BPIFA1 expression 43 and polymorphisms in the BPIFA1 gene 269 
are also associated with susceptibility to Epstein-Barr virus-associated 270 
nasopharyngeal carcinoma 44.  It will be of interest to determine if BPIFA1 affects the 271 
pathogenesis of other respiratory viruses. 272 
These studies have uncovered a significant and unappreciated role for 273 
BPIFA1 in host defense against experimental IAV infections in murine models. It 274 
remains to be seen if this protein is able to modulate IAV infection in the human host 275 
in a similar manner. The observation of elevated levels of BPIFA1 in nasal aspirates 276 
of children with IAV 45 suggests that some modulation of the protein does occur 277 
during clinical infection and thus is a potential biomarker.  We propose that BPIFA1 278 
may be one component of the airway surface lining fluid critical to antiviral host 279 
defense. Further studies are needed to determine if natural variations in BPIFA1 280 
levels due to genetic polymorphisms 44 may pre-dispose to more severe IAV-281 
associated disease. 282 
15 
 
283 
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 284 
Methods  285 
Virus.  286 
Influenza virus strains A/X-31 (X-31, H3N2) and A/PR/8/34 (PR8, H1N1) were 287 
propagated in the allantoic cavity of 9-day-old embryonated chicken eggs and titered 288 
by plaque assay on MDCK cells 46. 289 
Mice.  290 
Animal work was reviewed and approved by the local University of Liverpool Animal 291 
Welfare Committee and performed under UK Home Office Project Licences 40/2483 292 
and 70/8599.  Mice were all specified pathogen free and maintained under barrier 293 
conditions in individually ventilated cages. Transgenic Bpifa1-/- mice were bred at the 294 
University of Liverpool under UK Home Office Project Licence 70/8378. Transgenic 295 
mice deficient in BPIFA1 (Bpifa1-/-) and conditional knockout were generated 296 
(Bpifa1loxP; Scgb1a1-CreERTM) as described in S1 text and S1 Fig. Both transgenic 297 
strains were backcrossed 10 generations to C57BL/6J. Wild-type sex and age-298 
matched C57BL/6J control mice were purchased from Charles River (UK). 299 
Tamoxifen Administration.  300 
A 20 mg/ml Tamoxifen (tmx) stock solution was dissolved in Mazola corn oil. Tmx 301 
was administered by gavage of 0.25 mg per gram body weight to Bpifa1loxP; 302 
Scgb1a1-CreERTM adults daily for five days. Mice were then infected with IAV 4 days 303 
after the last gavage. 304 
Virus infection of mice.  305 
Animals were randomly assigned into multiple cohorts, anesthetized lightly with 306 
KETASET i.m. and inoculated intra-nasally with 103 pfu IAV in 50 µl sterile PBS, or 307 
were mock-infected with a similar volume of allantoic fluid. Mice were sacrificed at 308 
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variable time-points after infection by cervical dislocation. Tissues were removed 309 
immediately for downstream processing.  310 
Histology, Immunohistology.  311 
Histology and immunohistology (IH) was performed on paraformaldehyde-fixed, 312 
paraffin-embedded tissue using the peroxidase anti-peroxidase (PAP) method as 313 
previously described 47, 48. Primary antibodies used were rabbit anti-mBPIFA1 6 and 314 
goat anti-IAV (Meridian Life Sciences Inc., B65141G).   315 
Quantitative Histopathological Assessment.  316 
The percentage area and density of DAB staining within airway epithelium was 317 
quantified using whole slide images scanned and analyzed using Image-Pro Premier 318 
image analysis software version 9.1 (MediaCybernetics Inc.). An automated macro 319 
and app (named Trachea.ipp and Airways.ipx, respectively) were developed in 320 
conjunction with MediaCybernetics Inc. They were designed to identify and outline 321 
regions of interest comprising the airway epithelium of the trachea, bronchi and 322 
bronchioles, while excluding other cells. The macro and app analyze thresholds of 323 
hue, luminosity and saturation, which were set relative to the chromogen (DAB) 324 
utilized for BPIFA1 localization.  These data provided an average density of staining 325 
for each region of interest. The percentage area stained was defined as the brown 326 
area (positive immunostaining) divided by the total brown area plus blue area 327 
(hematoxylin; negative staining) ×100.  328 
Western Blotting.  329 
Samples were analysed by 12.5% SDS-PAGE gel electrophoresis and blotted using 330 
rabbit anti-mBPIFA1 6. Band density was measured using the gel analysis tool of 331 
Image J software. 332 
Quantitative protein analysis.  333 
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The Wes™ system was used to identify and quantify BPIFA1 protein in BAL and 334 
lung samples (ProteinSimple) and rabbit anti-mBPIFA1 as primary antibody. The 335 
area of BPIFA1 peak, in relation to the standard curve, was determined and virtual 336 
blot-like images generated using Compass software (ProteinSimple). 337 
Mouse tracheal epithelial cell cultures.  338 
Mouse tracheal epithelial cells (mTEC) were isolated and differentiated into upper 339 
airway-like epithelium in an air-liquid interface (ALI) culture following previously 340 
described methodology with slight modification 28, 29. Whole tracheas were excised 341 
from 6-8 weeks old mice. Five or six tracheas were pooled for each evaluation. 342 
 Immunofluorescent labeling and confocal imaging.  343 
Transwell membranes were fixed with 10% buffered formalin and then stained using 344 
primary and secondary antibodies.  Primary antibodies used were as follows: rabbit 345 
anti-BPIFA1 (1:200)6, rabbit anti-LPLUNC1 (1:100)6, mouse anti-β tubulin (1:100; 346 
Sigma Aldrich, Cat No- T5201), mouse anti-Foxj1 (1:100; eBioscience, Cat No- 14-347 
9965-82, Clone- 2A5), goat anti-SCGB1A1  (1:500; Gift from Barry Stripp), rabbit 348 
anti-MUC5B (1:100; Santa Cruz; H-300, Cat no- sc-20119,) and mouse anti-349 
Influenza A virus NP (anti-IAV NP; 1:200; H16-L10-4R5 (ATCC® HB-65™)). 350 
Secondary antibodies are as follows (all from Life Technology; 1:200): Alexa Fluor 351 
568 Goat anti-rabbit antibody (Cat No- A11011), Alexa Fluor 488 Goat anti-mouse 352 
antibody (Cat No- A11001), Alexa Fluor 488 Rabbit anti-goat antibody (Cat No- 353 
A11078), Alexa Fluor 633 Goat anti-mouse IgG (Cat No- A21050). Samples were 354 
mounted on glass slides with DAPI Vectashield (Vector Laboratories, Cat No- H-355 
1200) and visualized with an Olympus Fluoview 1000 Confocal microscope. 356 
Virus labeling and IAV binding assay.  357 
IAV A/PR/8/34 was purified from the allantoic fluid of infected eggs by pelleting 358 
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through a 30% sucrose/PBS cushion followed by banding on 15-60% sucrose/PBS 359 
density gradients. Virus was then labelled using a green Alexa-fluorophore labelling 360 
kit (Life Technologies) to yield Alexa Fluor 488-labelled virus (IAV-488). Unreacted 361 
dye was removed by pelleting the virus at 125,000 g. For binding assays, IAV-488 362 
was added to the apical surfaces of day 14 mTEC ALI cultures. After incubation for 1 363 
h and washing off unbound virus, membranes were immediately fixed with 10% 364 
buffered formalin and co-stained with anti-BPIFA1 and anti-FoxJ1 antibodies. 365 
Images were captured from at least five fields per sample by confocal microscope. 366 
Integrated fluorescence intensity was measured by Image J to assess the levels of 367 
IAV-488 binding on the cell surface of mTEC cultures. Three independent 368 
experiments were conducted with cells from three different batches of mice.  369 
Nuclear import assay of IAV ribonucleoprotein (vRNP) complexes.  370 
Apical surfaces of Day 14 ALI mTEC cultures were infected with purified IAV 371 
A/PR/8/34. Following infection, cells were overlaid with DMEM/F-12 media 372 
plus/minus cycloheximide (CHX) at a final concentration of 100 μg/ml (no CHX was 373 
the control). Cells were incubated in 5% CO2 at 37°C for 4 h, then washed three 374 
times with pre-warmed HBSS and fixed with 10% buffered formalin as above. 375 
Samples were processed and dual immunostained with anti-IAV NP as described 376 
above. Cells displaying nuclear localization of viral RNP were counted at 40x 377 
magnification in five fields (one center and four peripheral fields) per sample and 378 
presented as a percentage of positive cells over total cells counted. Three 379 
independent experiments were conducted with cells from three biologically different 380 
batches of mice.   381 
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Figure Legends 
Figure 1. BPIFA1 protein levels in BAL are modulated after IAV infection. BAL 
samples were taken from C57BL/6J mice infected with IAV X-31 at multiple days p.i. 
The Simple Western (Wes™; ProteinSimple) system was used to quantify BPIFA1 
protein using a rabbit anti-mBPIFA1 primary antibody. Equal amounts of protein (120 
μg as determined by BCA, Pierce) were loaded per lane. The area of the BPIFA1 
peak, in relation to the standard curve, was determined using Compass software 
(ProteinSimple). Bars represent mean ± SEM (n = 4). Statistically significant 
differences (One-way ANOVA with Tukey’s post-hoc analysis) between groups are 
represented by square brackets above. * represents p <0.05; ** represents p < 0.01. 
 
Figure 2. BPIFA1 level in airway epithelia is modulated after IAV infection. 
Lungs were dissected from C57BL6/J mice that were either mock- or IAV-infected 
(i.n. with 103 pfu IAV X-31) at multiple days p.i. as indicated. BPIFA1 was detected 
by IH using rabbit anti-mBPIFA1, visualized with DAB and counter-stained with 
hematoxylin. The percentage area of epithelium stained (left graph panels) and 
intensity of staining (right graph panels) in the trachea (A), bronchi (B) and 
bronchioles (C) were assessed by image analysis. Data are for four mice per group 
presented as mean + SEM. Statistically significant differences (One-way ANOVA 
with Tukey’s post-hoc analysis) between groups are represented by square brackets 
above. * represents p <0.05, ** represents p < 0.01, *** represents p < 0.001. 
Micrographs of representative areas at each time point are shown below the graph 
panels. Black arrows point to expression of BPIFA1 in respiratory epithelium. Scale 
bars represent; panel A: 50 µm, panel B: 10 µm and panel C:20 µm. 
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Figure 3. BPIFA1 influences the infection of mice by IAV. Panels A, B. 
C57BL/6J and Bpifa1-/- mice (n = 4 per group) were infected i.n. with 103 pfu IAV X-
31. Panel A. Mice were weighed daily and the weights represented as a percentage 
of the starting weight. Data represent the mean value ± SEM. Asterisks indicate 
statistical difference (two-way ANOVA with Bonferroni post-test; **represents p < 
0.01.  Panel B. Lung tissues were taken at multiple days p.i. as indicated and virus 
titer determined by plaque assay. Data represent the mean value ± SEM. Asterisks 
indicate statistical difference (two-way ANOVA with Bonferroni post-test; * represents 
p < 0.05, *** represents p < 0.001). Panel C. Bpifa1loxP; Scgb1a1-CreERTM mice 
were treated with either carrier (vegetable oil) or carrier plus Tamoxifen (tmx) by oral 
gavage five times as described in materials and methods. Lung tissue (n = 4 per 
group) was analyzed by western blotting for BPIFA1. Equal amounts (100 μg) of 
protein as determined by BCA (Pierce) were loaded per lane. The mean (± SEM) 
levels of BPIFA1 protein were measured by Image J as integrated band intensity. * 
represents statistical significance (Mann-Whitney U test; p < 0.05) BPIFA1 is clearly 
knocked down in the Tamoxifen-treated animals. Panel D. Tamoxifen-inducible, club 
cell specific BPIFA1 knockout mice (Bpifa1loxP; Scgb1a1-CreERTM) were dosed on 5 
consecutive days by gavage with 0.25 mg per gram body weight tamoxifen (tmx) or 
carrier (vegetable oil). Four days after the last gavage these mice, along with 
untreated Bpifa1loxP; Scgb1a1-CreERTM and Bpifa1-/- mice (n = 4 for all groups) were 
infected with IAV for 7 days. Lungs were collected and virus titer determined by 
plaque assay.  Data represent the mean value ± SEM. Asterisks indicate statistical 
difference (One-way ANOVA with Tukey’s post-hoc analysis; p < 0.05). 
 
33 
 
Figure 4. IAV spreads more rapidly in the absence of BPIFA1. C57BL/6J and 
Bpifa1-/- mice were infected i.n. with 103 pfu IAV X-31. Lung tissues were harvested 
at one day p.i. IAV antigen was detected by IH using goat anti-IAV, visualized with 
DAB and counter-stained with hematoxylin. Micrographs of representative areas 
from distal bronchioles and alveoli four mice are shown. Large arrows, positive 
epithelial cells. Red arrowheads, positive macrophages. 
 
Figure 5. BPIFA1 influences the infection of normal mTEC by IAV. mTEC ALI 
cultures were infected with IAV X-31 (0.1 pfu/cell). Panels A – F. Cells were 
processed and stained with anti-IAV NP (green), anti-mBPIFA1 (red), nuclei 
counterstained with DAPI (blue) and imaged using a confocal microscope. Scale bar 
represents 50 µm. Micrographs show representative areas from C57BL/6J mTEC 
cultures (A, B, C) and Bpifa1-/- mTEC cultures (D, E, F) at 2, 24 and 48 h p.i. (G) 
Mean integrated florescence intensity IAV nucleoprotein in mTEC ALI shown for 3 
independent biological replicates (± SEM). * represents p < 0.05, One-way ANOVA 
with Tukey’s post-hoc analysis. (H) Titer of IAV in apical wash. Data presented as 
mean ± SEM; n = 3; * represents p < 0.05, One-way ANOVA with Tukey’s post-hoc 
analysis. 
 
Figure 6. BPIFA1 decreases the nuclear import of IAV RNPs into normal mTEC. 
mTEC ALI cultures from wt C57BL/6J or Bpifa1-/- mice were incubated with purified 
IAV A/PR/8/34 in the presence or absence of cycloheximide (CHX) as indicated. 
Cycloheximide blocks protein synthesis and so indicates the import of pre-existing 
IAV RNP from incoming virus particles. After 4 h incubation at 37°C cultures were 
processed and stained with anti-IAV NP and counter-stained with DAPI before 
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visualization using a confocal microscope. Scale bar represents 50 μm. (A) 
Representative micrographs from cultures incubated with IAV in the absence or 
presence of CHX (B) micrographs from cultures incubated with IAV in presence of 
CHX at a higher magnification. (C) Nuclei that were positive for IAV NP in the 
presence of cycloheximide were counted at 40x magnification in five fields (one 
center and four peripheral fields) per sample and presented as a percentage of 
positive cells over total cells counted. The mean percentage positive nuclei are 
shown for 3 independent biological replicates (± SEM). * represents statistical 
significance (One-way ANOVA with Tukey’s post-hoc analysis; p < 0.05)  
 
Figure 7. BPIFA1 restricts binding of IAV to normal epithelial cells in mTEC ALI 
cultures. mTEC ALI cultures were incubated for 1 h with IAV Alexa-fluor 488-labeled 
purified IAV A/PR/8/34 (IAV-488), then fixed with formalin, stained with anti-BPIFA1 
and anti-FoxJ1 antibodies and then imaged using a confocal microscope (A) 
Representative images of two different fields of day 14 C57BL/6J mTEC ALI culture 
showing IAV-488 (green) preferentially binding to FoxJ1-positive (white) ciliated cells 
but not BPIFA1 (red)-positive cell populations (circled by yellow dotted line). (B) 
Micrograph showing IAV-488 binding (green) with the epithelium of wt C57BL/6 and 
Bpifa1-/- cultures. (C) Integrated florescence intensity of IAV-488 virus binding with 
the surfaces of mTEC culture. Images were captured from at least five fields per 
sample by confocal microscope at 20x, 40x and 60x magnification. The levels of IAV-
488 binding on mTEC cell surfaces were measured by Image J as integrated 
fluorescence intensity. The mean fluorescent intensity is shown for 3 independent 
biological replicates (± SEM). * represents statistical significance (Mann-Whitney U 
test; p < 0.05)  







Supplementary Data 
Results 
Generation of transgenic mice deficient in BPIFA1.  
Animal procedures for generation of the Bpifa1loxP and Bpifa1-/- transgenic lines were 
approved by the Institutional Animal Care and Use Committee at University of Hawaii 
under protocols 07-056 and 11-1112.  
A conditional targeting vector for Bpifa1 used for transfection of C57BL/6J 
mouse embryonic stem cells was constructed by InGenious Targeting Laboratory, Inc. 
(Ronkonkoma, NY). The targeted region on the Bpifa1 gene includes exons 2-3 (see 
S1 Fig. A).  
Embryonic stem cells were microinjected into BALB/c blastocysts. Resulting 
chimeras with a high percentage black coat color were mated to wild-type C57BL/6J 
mice to generate F1 heterozygous offspring. Correctly targeted F1 mice contained a 
Neo-selection cassette, three lox-P sites and two FRT sites. 
Deletion of the Neo-cassette was achieved by breeding with a heterozygous 
C57BL/6J background FLP+/- mouse (Jackson Laboratories, JAX; stock 003800). 
Since these FLP mice are heterozygotes (homozygotes are embryonic lethal), the 
resulting F2 mosaic mice were screened for presence of the FLP transgene and 
deletion of the Neo cassette. After breeding with C56BL/6J mice, the resulting F3 
generation was screened for FLP transgene absence and deletion of the Neo cassette. 
This mouse was bred with another heterozygous FLP-/- and Neo-/- F3 offspring to 
produce a homozygous floxed F4 mouse without the FLP transgene and without the 
Neo cassette (Bpifa1loxP).  
To generate a systemic Bpifa1 KO mouse (Bpifa1-/-), Bpifa1loxP mice were 
mated with a mouse containing the Cre-recombinase transgene under the control of 
hCMV IE promoter (CMV-Cre, formally B6.C-Tg(Tg (CMV-Cre)1Cgn/J; JAX Stock 
No: 006054; see S1 Fig. A).  
Bpifa1loxP and Bpifa1-/-  mice were deposited at the MRC Mammalian Genetics 
Unit (Harwell, UK; FESA:5217 and 5945 respectively) and then transferred from there 
to the University of Liverpool. 
 To generate a conditional, club cell-specific KO mouse (Bpifa1loxP; Scgb1a1-
CreERTM), Bpifa1loxP mice were mated with Scgb1a1-CreERTM (Scgb1a1tm1(cre/ERT)Blh ; 
Jackson Lab, stock 016225) >1@. These mice express a tamoxifen-inducible form of 
cre recombinase from the Scgb1a1 locus (secretoglobin).  
 
Phenotyping of Bpifa1-/- mice.   
Four wild type (wt) mice (C57BL/6J) and four Bpifa1-/- mice, two males and two 
females of each, aged 6 – 10 weeks, were examined grossly and histologically for 
phenotypical differences as a result of lack of expression of the Bpifa1 gene. There 
were no differences grossly. Histological examination of the lymphoid, gastrointestinal, 
urinary, cardiovascular, endocrine, reproductive organs and the CNS was 
unremarkable. In addition to the respiratory tract, BPIFA1 is expressed in minor glands 
of the nose, sinuses, posterior tongue and tonsil >2, 3@, in some of the seromucous 
cells of the major salivary glands and is detectable in saliva. In glandular tissues 
examined (submandibular, parotid and sub-lingual salivary glands, minor tongue (von 
Ebner’s) gland, Zymbal’s gland, Harderian gland and lacrimal gland), the only 
difference noted was that the eosinophilic granules within the epithelium of the 
convoluted tubules of the submandibular salivary glands, which are prominent in male 
mice only, were far less striking in the male Bpifa1-/- mice. The serous and mucous 
glands were unaffected, and Alcian blue (AB) and periodic acid-Schiff (PAS) staining 
yielded similar results in both wt and Bpifa1-/- mice in these glands (data not shown). 
The tissues of the upper and lower respiratory tract were examined using H&E, 
AB and PAS stains, as well as immunohistology (IH) for BPIFA1 and SCGB1A1. 
Tissues from Bpifa1-/- were consistently IH-negative for BPIFA1, and there were no 
differences in the intensity or distribution of SCGB1A1 immunostaining between the 
wt and the Bpifa1-/- mice.  In Bpifa1-/- mice the nasal respiratory epithelial cells at the 
transition to the olfactory epithelium generally exhibited abundant hyalinized globular 
cytoplasmic material, leading to expansion of the cells (S1 Fig C). This is a common 
finding in many strains of mice and increases in severity with age >4-6@ but is of interest 
as in the present study it was only present in the Bpifa1-/- mice, and at this young age. 
In the trachea, bronchi and lower respiratory tract, no phenotypical differences were 
noted between the wild type and Bpifa1-/- mice.  
 
Normal tracheal epithelial cultures (mTEC) are a good model to study IAV 
infection in vitro.  
Normal mouse tracheal cell cultures were established from C57BL/6J mice and 
cultured at the air-liquid interface to generate well-differentiated cultures (mTEC). 
Differentiated mTEC ALI cultures displayed phenotypic features associated with a 
complex population of ciliated cells (β-tubulin), BPIFA1, mucin (MUC5B), Foxj1 (cilia 
marker) and SCGB1A1 (CCSP)-expressing cells that matched with the features of the 
native rodent airway epithelium (S3 Fig. A, C, D, E).  The surface topology of day 14-
differentiated mTEC ALI cultures also showed ciliated epithelial cells interspersed with 
domed shaped non-ciliated cells with a cobble stone appearance, which is typical of 
the upper airway morphology (S3 Fig. B). The expression of a selected cohort of 
airway epithelium-specific genes was also assessed in 14-day cultures to further 
validate our in vitro model. SCGB1A1 (a club cell marker), and BPIFB1 (LPLUNC1) 
gene expression was present but relatively low when compared with mTEC original 
cells (freshly isolated mTEC cells without culture modification) (S3 Fig. F). BPIFA1 
was readily detected in cultured epithelial cells and within the apical secretions (S3 
Fig. A, G) but was not found in ciliated cells (S3 Fig. A, C). Airway epithelium-
associated genes, Bpifa1, Bpifb1, Scgb1a1, Muc5ac, Muc5b, Tekt-1 (a cilia gene) 
were consistently expressed in Day-14 mTEC ALI cultures and matched with the 
original cell gene expression signature of the mTECs (S3 Fig. F). The in vitro tracheal 
cultures are thus a good in vitro model with which to study BPIFA1 biology during IAV 
infection.  
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Supplementary Figure Legends 
S1 Fig. Construction and characterisation of Bpifa1loxP and Bpifa1-/- mice 
Panel A (i).  Wild-type Bpifa1 locus. The targeted region on the Bpifa1 gene includes 
exons 2-3.  (ii). Targeting vector. The conditional targeting vector contained exons 2 
and 3 flanked by LoxP sites and a Neo selection cassette flanked by FRT sites. (iii). 
Deletion of the Neo-cassette was achieved by breeding with a heterozygous C57BL/6J 
background FLP+/- mouse to generate conditional targeted Bpifa1loxP mice. (iv). To 
generate a systemic Bpifa1 KO mouse (Bpifa1-/-), Bpifa1loxP mice were mated with a 
mouse containing the Cre-recombinase transgene under the control of hCMV IE 
promoter.  
Panel B. Western blot analysis of lung tissue from either wild-type C57BL/6J or Bpifa1-
/- mice (as indicated) using rabbit anti-BPIFA1 as primary antibody. The first lane 
shows the molecular weight markers. A characteristic 27-31 kDa doublet was 
observed corresponding to alternatively-glycosylated forms of BPIFA1 in the wild-type 
but not Bpifa1-/- mice. 
Panel C. Nasal cavities of C57BL/6J and Bpifa1-/- mice were dissected, processed for 
histology and stained with hematoxylin/eosin.  In Bpifa1-/- mice there was hyalinised 
globular cytoplasmic material present in the respiratory epithelium at the transition to 
olfactory epithelium shown by black arrows. Micrographs of representative areas from 
four mice are shown. 
 
S2 Fig. IAVspecific staining in mice at 1 day p.i.  C57BL/6J and Bpifa1-/- mice were 
infected i.n. with IAV X-31. Lung tissues were taken at one day p.i. IAV antigen was 
detected by IH using goat anti-IAV, visualized with DAB and counter-stained with 
hematoxylin. Micrographs of representative areas from four mice are shown. Large 
arrows, positive epithelial cells. 
 
S3 Fig. Validation normal tracheal epithelial cell (mTEC) model. Tracheal 
epithelial cells were prepared from C57BL/6J mice and differentiated at the air-liquid 
interface for 14 days. (A) Confocal image showing cells stained for β-tubulin (ciliated 
cells; green) and BPIFA1 (red). The Z-slice (side panels) shows BPIFA1 cells are non-
ciliated. (B) Scanning electron micrograph of the apical surface of the mTEC cultures 
showing ciliated cells and non-cilated cells with a cobble-stone appearance. (C, D, E) 
Confocal images showing BPIFA1 and FoxJ1 (C), MUC5B (D) and SCGB1A1 (E) in 
day 14 ALI cultures of WT mTECs. (F) RT-PCR showing airway epithelium associated 
gene expression profile of mTEC ALI culture of WT (representative of three 
independent cultures). The OAZ-1 gene was used as housekeeping gene >7@ (G) 
Western blot on apical washes collected from WT mTEC-ALI culture (representative 
of three independent cultures). Scale bar for confocal images represents 50 µm. 
 
S4 Fig. Validation of the phenotype of mTEC ALI cultures from Bpifa1-/- mice. 
mTEC ALI cultures from wild-type C57BL6/J and Bpifa1-/- mice were analyzed by 
confocal microscopy.  Micrographs show representative areas from three separate 
cultrues. Panels A, B. Cells were processed and stained with anti-β-tubulin (cilia 
marker; green), anti-mBPIFA1 (red) and nuclei counterstained with DAPI (blue). 
Panels (C, D) Cells were processed and stained with anti-MUC5B (mucin secreting 
cells; red) and nuclei counterstained with DAPI (blue). Scale bar represents 50 µm. 
 
S5 Fig. Detection of Į2,3 and Į2,6linked sialic acid residues on uninfected 
mTEC. The presence of α2,3-linked sialic acid (SA) and α2,6-linked SA residues on 
the surface of cells was detected by binding of fluorescein-labelled lectins from 
Maackia amurensis (MAA) and Sambucus nigra (SNA), respectively. Uninfected day 
14 ALI cultured mTECs were dual-labelled with either anti-BPIFA1 plus MAA or anti-
BPIFA1 plus SNA. (A) α2,3-linked SA receptor expression (detected by MAA) was 
present in both wt and Bpifa1-/- mTEC cultures. Interestingly, the BPIFA1+ cell 
population was absolutely devoid of α2,3-linked SA residue expression. (B) α2,6-
linked SA receptor expression (detected by SNA) was only seen in a low proportion of 
cells in both wt and Bpifa1-/- mTECs. (C, D, E) Occasional expression of α2,6-linked 
SA residues was detected in BPIFA1+ mTECs. This is a representative result from 
three separate experiments on two batches of mice. Scale bar represents 20 µm. 
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